Evidence mapPaperPMID 42266880Full record

ArticleTherapeutics and clinical risk management2026

Association Between Insulin Regimen and Cardiovascular Risk in Indonesian Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Ramdhani M Natsir, Eli Halimah, Ajeng Diantini, Jutti Levita

Abstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ramdhani M Natsir *Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0003-4172-3064
Eli Halimah *Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-7812-8982
Ajeng Diantini *Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0003-2258-5137
Jutti Levita *Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-4578-4174

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among patients with type 2 diabetes mellitus (T2DM). Despite the widespread use of insulin therapy, evidence on how different insulin regimens influence cardiovascular risk stratification remains limited and inconsistent, particularly in Asian populations, including Indonesia. Purpose: To evaluate the association between insulin regimens and cardiovascular risk, as assessed by the Framingham Risk Score (FRS), among patients with T2DM. Methods: A cross-sectional study was conducted involving 118 patients with T2DM receiving insulin therapy, including basal insulin therapy and combined basal-prandial insulin therapy. Cardiovascular risk was assessed using the FRS and categorized as low, moderate, or high. Differences between groups were analyzed using the Chi-square test. The association between insulin regimen and cardiovascular risk was evaluated using ordinal logistic regression. Results: Most patients in both treatment groups were classified as having high cardiovascular risk according to the FRS. After adjustment for potential confounders, the insulin regimen was not significantly associated with cardiovascular risk (OR = 2.14; 95% CI: 0.81-5.65; p = 0.124). In contrast, the duration of T2DM was significantly associated with cardiovascular risk (OR = 3.63; 95% CI: 1.30-10.15; p = 0.014). Conclusion: Cardiovascular risk among patients with T2DM receiving insulin therapy was predominantly moderate to high. The insulin regimen was not significantly associated with cardiovascular risk, whereas the duration of T2DM played a more prominent role in cardiovascular risk stratification.

Indexed as

cardiovascular diseasecholesterolinsulin therapytype 2 diabetes mellitus

Identifiers

PMID42266880
PMCPMC13242994

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.